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ABSTRACT
Background: Inhaled hypertonic saline (HTS)
improves quality of life and reduces pulmonary
exacerbations when given long term in patients with
cystic ﬁbrosis (CF). While increasingly being offered
for acute pulmonary exacerbations, little is known
about the efﬁcacy in this setting.
Objectives: The authors examined the tolerability and
efﬁcacy of HTS use among adult subjects hospitalised
with a CF pulmonary exacerbation and hypothesised
that use of HTS would improve pulmonary function
during the admission.
Design: Pilot retrospective non-randomised study.
Setting: Single tertiary care centre.
Participants: 45 subjects admitted to the inpatient
service for acute CF pulmonary exacerbation in
2006e2007. A subset of 18 subjects who were also
admitted in 2005 when HTS was not available was
included in the comparative study.
Primary outcome: Change in forced expiratory
volume in one second from admission to discharge.
Secondary outcomes: Change in weight from
admission to discharge and time to next exacerbation.
Results: Mean age was 32.5 years, and mean length of
stay was 11.5 days. HTS was offered to 33 subjects
and was well tolerated for a total use of 336 days out
of 364 days of hospital stay. Baseline demographics,
lung function and sputum culture results were
comparable in ﬁrst and second visits. Use of HTS was
not associated with an improvement in forced
expiratory volume in one second (p¼0.1), weight gain
(p¼0.24) or in the time to next admission (p¼0.08).
Conclusions: These pilot data suggest that HTS is well
tolerated during CF pulmonary exacerbation but offers
no clear outcome beneﬁts. It is possible that HTS may
not have much advantage above and beyond intensive
rehabilitation and intravenous antibiotics and may add
to hospital costs and treatment burden.
BACKGROUND
Lung disease is the leading cause of
morbidity and mortality in patients with
cystic ﬁbrosis (CF). It is characterised by
chronic bacterial colonisation and recurrent
infections of the airways, which have been
evident manifestations of the disease since
the term ‘cystic ﬁbrosis’ was ﬁrst coined.
1 2
Mutations in the CF transmembrane
conductance regulator gene result in defec-
tive epithelial chloride transport in human
airway epithelia, but the downstream conse-
quences of this defect and how they result
in CF lung disease remain to be further
elucidated.
34The clinical course of patients
with CF is characterised by periods of ‘stable’
disease, interspersed by recurrent
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- Long-term use of inhaled HTS improves pulmo-
nary function and decreases exacerbation
frequency in patients with CF.
- Despite lack of available data regarding efﬁcacy
and safety, inhaled HTS is frequently used during
hospitalisation for exacerbation of CF pulmonary
disease.
Key messages
- This retrospective non-randomised study
suggests that inhaled HTS is well tolerated
during hospitalisation for exacerbation of CF
pulmonary disease.
- Short-term (14 days) use of inhaled HTS
provided no added improvement over standard
care (intravenous antibiotics and chest physical
therapy) in pulmonary function, weight gain or
time to next hospitalisation.
Strengths and limitations of this study
- This study allowed within-patient comparison of
standard treatment with or without inhaled HTS
in a relatively homogeneous adult population in
an inpatient setting.
- The main limitation of this study is the
retrospective and non-randomised design and
unavailability of detailed compliance and side
effect data. Sample size was adequate for the
objectives of the study.
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Open Access Researchexacerbations during which symptoms such as sputum
production and cough tend to acutely increase in
intensity and are associated with increased bacterial
density in the lungs and hypoxaemia.
5e8
During acute CF lung disease exacerbation, usual
treatment involves intravenous antibiotics, enhanced
nutritional supplementation and airway clearance ther-
apies (eg, frequent chest physiotherapy, inhaled albu-
terol, aerobic exercise).
7 9 Inhaled rhDNase can improve
pulmonary function when used long term, albeit at
a relatively high cost.
10e12 Inhaled hypertonic saline
(HTS) is an attractive addition because it is inexpensive,
fairly well tolerated and acutely increases whole-lung
mucus clearance. Long-term treatment with inhaled
HTS has been shown to improve pulmonary function
and decrease exacerbation frequency.
13e18 However,
HTS use during an exacerbation may be potentially
more harmful by causing more bronchospasm or
haemoptysis. To our knowledge, no studies have exam-
ined the safety proﬁle and efﬁcacy of inhaled HTS
treatment given during CF pulmonary exacerbation.
In this pilot retrospective study, we examine the impact
of HTS use among a cohort of adult subjects hospitalised
with CF pulmonary exacerbation compared with the
same group of subjects during a previous exacerbation
when HTS was not used. We hypothesised that use of
inhaled HTS in addition to standard care during
hospitalisation for acute exacerbation of CF would result
in greater improvement in common end points such as
pulmonary function, body weight and the time to next
exacerbation when compared with standard of care.
METHODS
The study was approved by the University of Iowa Insti-
tutional Review Board (200710793). This is a retrospec-
tive chart review of all adult admissions for CF lung
disease exacerbation at the University of Iowa Hospitals
and Clinics during the years 2006 and 2007 when
inhaled HTS was ﬁrst offered to patients. Standard care
consists of intravenous antibiotics chosen based on the
most recent sputum culture and susceptibility testing,
nutrition supplementation, pulmonary rehabilitation
and intensive mucus clearance techniques such as chest
physical therapy four times per day. Study subjects had
a diagnosis of CF based on a sweat chloride test or a nasal
voltage test, and genotyping of the CFTR gene. For the
comparative study, data were abstracted from the
admission during which HTS (‘second visit’) was ﬁrst
used and compared with an earlier admission in the
previous year (2005) in which HTS was not used (‘ﬁrst
visit’).
Variables studied include age and gender, body mass
index on admission and discharge, duration of hospital-
isation, intravenous antibiotics use, CF mutation, use of
chest physical therapy, sputum culture results, time to
next exacerbation and HTS use during subsequent
hospitalisations. Baseline pulmonary function values were
obtained from testing performed on admission day or in
the previous 7 days. During admission, pulmonary func-
tion testing was performed twice a week. One subject was
discharged after 2 days with a peripherally inserted
central catheter to complete antibiotics at home. Subjects
received an inhaled b2 agonist to minimise the risk of
bronchospasm followed by a 4 ml dose of 7% HTS solu-
tion twice daily through a Pari LC nebuliser (PARI
Respiratory Equipment, Midlothian, VA, USA). Compli-
ance data are reported as total days of HTS use per total
hospitalisation days in the study population. For the
comparison study, only subjects who used HTS at least
7 days were included. Main outcome variable of
comparison was change in per cent of predicted forced
expiratory volume in one second (FEV1) from baseline to
discharge. Subjects who failed to reach 90% of their best
per cent of predicted FEV1 in the 6 months previous to
hospitalisation were deﬁned as non-responders to
therapy.
19 Other outcomes analysed include length of
stay, compliance, time to next admission and weight gain.
Power analysis
Power analysis suggested a paired sample size of 18
patients to detect a change of 10.9% in FEV1 (primary
outcome) or weight with a conservative between-group
SD of 16%, with 80% power at two-tailed a of 0.05.
Observed power analysis for primary and secondary
outcomes is detailed in the Discussion section.
Outcomes analysis
Data were analysed using Prism 5 for Mac OS (Graphpad
Software) and SAS V.9.2 (SAS Institute). Power analysis
was performed using Statmate (Graphpad Software).
Univariate data are reported as means and SD and
proportions. Paired t test was used for comparisons using
a 5% level of signiﬁcance. Mixed models for repeated
measures were used to compare FEV1 change from
baseline in the comparison study. Fisher’s exact test was
used to compute p value of contingency analysis of ‘non-
responders’ and ‘responders’ in both visits and to
analyse categorical data in table 1.
RESULTS
Study participants
Between January 2006 and December 2007, 45 subjects
were admitted to the CF inpatient service at the Univer-
sity of Iowa Hospitals and Clinics. Mean age at admission
for this subject population was 32.5610.1 years, and
mean length of stay was 11.164.1 days (p>0.05, unpaired
t test). Forty-six per cent of these subjects were men. Of
the 45 subjects, 25 had an admission in the previous year.
All 25 subjects had pulmonary function testing
performed around time of admission and at discharge.
Of these 25 subjects, 18 had no history of asthma or
recent haemoptysis and thus inhaled HTS was offered.
These 18 subjects were therefore included in the
comparative study as described in the Methods section.
Baseline characteristics at admission for subjects who
fulﬁlled inclusion criteria into the comparative study are
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Hypertonic saline for cystic ﬁbrosis exacerbationsshown in table 1. During the entire study period, use of
HTS at home prior to admission was uncommon (0% of
subjects during the ﬁrst visit and 5% during the second
visit). The proportion of patients using inhaled tobra-
mycin or rhDNase was similar prior to both admission
(p>0.05), and the prevalence of colonisation with Pseu-
domonas aeruginosa or Staphylococcus aureus was also similar
in both admissions (p>0.05).
HTS is well tolerated by the majority of subjects
hospitalised for acute exacerbation of CF
During the study period, inhaled HTS was offered to 34
out of 45 subjects, of whom 33 used it for at least 1 day.
The remaining 11 subjects were not offered inhaled
HTS due to history of asthma or recent haemoptysis.
Among 33 subjects, there was a collective use of HTS for
a total of 336 days out of 364 days of hospitalisation. Of
the 28 total discontinuation days, 24 were explained by
side effects (wheezing and mild haemoptysis) in two
subjects. Twenty-seven subjects used HTS for more than
7 days. These data suggest that inhaled HTS is well
tolerated by subjects hospitalised for exacerbation of CF
lung disease.
HTS does not improve pulmonary function during
hospitalisation for acute exacerbation of CF
Among the 18 subjects included in the comparative
study, average change in percentage predicted FEV1
from baseline to discharge (in percentage points) was
12.2% (95% CI 7.7% to 16.5%) when HTS was not used
and 8.9% (95% CI 4.9% to 12.9%) when HTS was used
(ﬁgure 1A), suggesting that inhaled HTS resulted in
decreased improvement in FEV1 at discharge (p¼0.02,
95% CI 0.5% to 5.9%). However, the mean percentage
predicted FEV1 at admission was higher when HTS was
used (p¼0.04) (ﬁgure 1B), while the average discharge
FEV1 values were not signiﬁcantly different (p¼0.46)
between the two visits (ﬁgure 1C). The data suggest that
the decrease in FEV1 improvement when inhaled HTS
was used is therefore likely due to a higher admission
FEV1 during that hospitalisation. A mixed-model
adjustment for the differences in FEV1 at baseline
Table 1 Patient characteristics during admission*
Characteristic First visit Second visit
Age (years), mean 6 SD 33.669.5 35.069.3
Male, % (n) 77 (14) 77 (14)
Body mass index (kg/m
2), mean 6 SD 20.863.2 21.763.5
FEV1 (per cent of predicted), mean 6 SD 39.8613.9 44.2616.4
FVC (l), mean 6 SD 2.761.1 3.261.2
ΔF508 homozygous, % (n) 61 (11) 61 (11)
Inhaled tobramycin use, % (n) 11 (2) 16.6 (3)
Inhaled HTS use at home, % (n) 0 (0) 5 (1)
Inhaled rhDNase use at home, % (n) 50 (9) 33 (6)
Pancreatic insufﬁciency, % (n) 83 (15) 83 (15)
Diabetes mellitus, % (n) 39 (7) 39 (7)
Pseudomonas aeruginosa in sputum, % (n) 72 (13) 83 (15)
Sputum density of P aeruginosa (log CFU), mean 6 SD 7.167.0 7.066.9
Staphylococcus aureus, % (n) 33 (6) 39 (7)
Length of stay (d), mean 6 SD 13.063.9 12.064.5
Characteristics on admission for subjects included in comparative study. The admission (year 2005) in which HTS was not used (ﬁrst visit) was
compared with the admission (year 2006 or 2007) in which HTS was used (second visit). n¼18.
*p Value for all variables (except FEV1/FVC) >0.05.
CFU, colony forming units; FEV1, forced expiratory volume in one second; FVC, forced vital capacity; HTS, hypertonic saline.
Figure 1 Forced expiratory
volume in one second (FEV1). The
admission (year 2005) in which
hypertonic saline was not used ( )
was compared with the admission
(year 2006 or 2007) in which
hypertonic saline was used (+). (A)
Change from admission to
discharge FEV1. Units are change
in total percentage of predicted.
Mean 6 95% CI are shown. Per
cent predicted FEV1 at admission
(B) or discharge (C). Units are
percentage of predicted. Lines join
data from both visits for the same subject. n¼18. *p#0.05; NS, p>0.05.
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Hypertonic saline for cystic ﬁbrosis exacerbationsshowed no changes in FEV1 improvement when inhaled
HTS was used (p¼0.10). Next, we analysed the number
of subjects who failed to reach at least 90% of their best
per cent FEV1 in the 6 months prior to admission at the
end of hospitalisation. This strategy attempts to mini-
mize the confounding effects of week-to week variability
in FEV1.
19 Four subjects were ‘non-responders’ when
HTS was not used and two when HTS was used (p¼0.65).
Overall, these data suggest that use of inhaled HTS
during hospitalisation for exacerbation of CF lung
disease does not result in improved or worsened FEV1
over standard of care in this small population.
HTS does not augment weight gain during hospitalisation for
acute exacerbation of CF
In our experience, subjects hospitalised for exacerbation
of CF lung disease gain weight during the visit, probably
as a result of enhanced caloric intake and/or control of
the inﬂammatory state in the lungs resulting from
infection. Figure 2 shows that the addition of inhaled
HTS was not associated with an improved or worsened
weight gain during hospitalisation. Average weight gain
was 3.4% (95% CI 0.44% to 6.3%) when HTS was not
used and 1.5% (95% CI  1.3% to 4.3%) when HTS was
used (p¼0.24, 95% CI  1.4 to 5.0).
HTS does not increase time to next admission after an acute
exacerbation of CF
Since inhaled HTS was used during hospitalisation but
not as outpatient in our clinical practice through this
study period and in the year 2008, we were able to study
the effect of inpatient HTS on time to next admission for
pulmonary exacerbation. Average time to next admis-
sion was 247 days when HTS was not used (95% CI 154
to 340 days) and 176 days when HTS was used (95% CI
98 to 253 days). Figure 3 shows that HTS was associated
with decrease time to next admission, but this decrease is
not statistically signiﬁcant (p¼0.08, 95% CI  9.8 to
152.7). Failure of increase in the time to next admission
is probably related to short-term use of HTS in this study.
CONCLUSIONS
In this retrospective pilot study of subjects hospitalised
for exacerbation of CF lung disease, use of inhaled HTS
was not associated with additional beneﬁt over standard
treatment, which includes intravenous antibiotics,
enhanced nutritional supplementation and airway
clearance therapies. Two recently published studies
showed that inhaled HTS improved outcomes in subjects
with CF presumably by hydration of airway surface liquid
and improved clearance of airway secretions. HTS can
improve pulmonary function and mucus clearance in
patients with stable CF lung disease even when used for
a short time (2 weeks).
13 20 In a large, multicentre
randomised controlled trial of stable subjects with CF,
twice daily inhalation of 7% HTS over 48 weeks was
shown to decrease exacerbation frequency compared
with isotonic saline.
15 The decrease in exacerbation
frequency can also be observed in later stages of the
disease.
21 The only study of inpatient use of HTS to our
knowledge is a study of hospitalised infants with viral
bronchiolitis, where nebulised 3% HTS was well toler-
ated and reduced length of stay signiﬁcantly.
22 In
another recent study, 7% HTS was found to be safe and
well tolerated in infants with CF.
17
Figure 2 Change from baseline weight. The admission (year
2005) in which hypertonic saline was not used ( ) was
compared with the admission (year 2006 or 2007) in which
hypertonic saline was used (+). Units are per cent change in
weight from admission to discharge. n¼18. Data ¼ mean 6
95% CI. NS, p>0.05.
Figure 3 Time to next admission. The admission (year 2005)
in which hypertonic saline was not used ( ) was compared
with the admission (year 2006 or 2007) in which hypertonic
saline was used (+). Units are number of days between
discharge and next admission with a diagnosis of acute
exacerbation of cystic ﬁbrosis lung disease. n¼18. Data ¼
mean 6 95% CI. NS, p>0.05.
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Hypertonic saline for cystic ﬁbrosis exacerbationsPatients admitted for exacerbation of CF lung disease
have been offered inhaled HTS as an adjunct to
conventional therapy in our institution (and others-
verbal communication). The decision to use inhaled
HTS is based on the premise that the beneﬁt will
outweigh the risk of adverse events (which have been
minimal in most studies) and the low cost and ease of
administration of this agent.
10e12 14 15 23e26 However,
inhaled HTS can induce cough
10e12 14 20 23 24 26 in
human subjects and has been used to provoke bron-
choconstriction.
25 27 In previous studies of inhaled HTS
for CF, cough and dyspnoea have been the reasons for
discontinuation of use and exclusion from study.
14 20 23 24
Increased airway inﬂammation could cause hospitalised
patients to be particularly susceptible to HTS-induced
bronchospasm. One of the primary aims of this study was
to examine the tolerability of HTS in this high-risk
population. We did not observe an increased incidence
of bronchospasm or worsening obstructive physiology
when HTS was used.
A recent analysis of risk factors that are associated with
failure to recover to spirometric baseline (at least 90% of
the best FEV1 in the 6 months previous to an exacerba-
tion) after intravenous antibiotic treatment reported
that approximately 25% of subjects fail to recover at least
3 months after the episode.
19 In our study, four out of 18
subjects failed to recover to spirometric baseline at
discharge when HTS was not used, whereas two out of 16
failed to do so when HTS was used. This analysis also fails
to demonstrate signiﬁcant beneﬁt of using HTS during
acute exacerbation of CF, although the data from both
studies are not directly comparable since patient popu-
lations with different characteristics are analysed.
Why were we unable to detect any improvement in
pulmonary function tests or weight gain in this group of
CF inpatients? In contrast to previous studies,
13 15 this
group of subjects do not present with stable lung disease.
In a patient with acute exacerbation who is already
receiving maximal treatment including intravenous
antibiotics, chest physical therapy and rhDNase, the
additional beneﬁt of HTS could be trivial because of
a ceiling effect. The fact that admission FEV1 during the
visit in which HTS was used was generally higher while
discharge FEV1 was similar in both visits also supports
a possible ceiling effect, in which only a certain degree of
improvement may be possible, even with maximal
therapy.
Limitations of this study include retrospective nature of
data collection from a single institution and unavailability
of detailed compliance and side effect proﬁles. Due to
its inherent retrospective nature, this study is non-rand-
omised and does not beneﬁt from intention-to-treat
analysis. Although we examined several variables such as
FEV1, sputum microbiology and co-interventions, there
may be other unmeasured biases between the two
admission time periods that may have diluted or masked
the treatment effect. Observed power analysis reveals that
our sample size and data distribution allow us to detect
a difference of at least 3.6% FEV1 (primary outcome)
between admission and discharge FEV1 with 80% power
(18 pairs, SD between groups of 5.44). These data will be
useful for adequate power analysis prior to future related
studies. The sample size is too small to allow subgroup
analysis based on factors, such as baseline FEV1 and age.
For the secondary outcome of weight gain (14 pairs, SD
between groups of 5.65), our sample size allows detection
of 4.23 kg in weight gain difference between admissions.
In the case of time to next admission (18 pairs, SD
between groups of 163.44), which was a more variable
outcome, our sample size allows detection of a change of
107 days or more. The absence of increased weight gain
from using HTS during hospitalisation could be the
result of insufﬁcient follow-up time, although a long-term
study also failed to demonstrate a beneﬁt.
15
This study also highlights an important clinical
dilemma in CF patient care. In the last decade, at least
ﬁve new agents have shown beneﬁts compared with
placebo.
28 These valuable, placebo-controlled rando-
mised control trials for new treatments, however, do not
analyse synergy or interaction with other therapies. In
real-world applications, the clinician must apply ‘new’
therapy in conjunction with standard treatments (eg,
airway clearance techniques) and other relatively new
therapies (eg, rhDNase). Questions such as ‘How should
the clinician prioritise these therapies?’ and ‘Are there
important interactions between these therapies?’ have
been raised by those writing consensus documents for CF
practice.
29 The results of the current study demonstrate
the importance of addressing these questions in well-
planned clinical trials since the outcomes of ‘uncon-
trolled’ combinations in clinical practice are unpredict-
able. A recently registered prospective randomised
controlled trial (ANZCTR # ACTRN12605000780651)
may provide clearer answers regarding the role of inhaled
HTS during hospitalisation for exacerbations of CF lung
disease.
In conclusion, in this study, use of inhaled HTS during
hospitalisation for acute exacerbation of CF was not
associated with FEV1 improvement, additional weight
gain or increased time to next admission over standard
treatment in this retrospective study. The question of
whether clinicians should offer or withhold this treat-
ment to patients hospitalised for an exacerbation of CF
will require a well-controlled therapeutic combination
type studies showing added efﬁcacy without added
burden. As new therapies are expected, the CF research
community will increasingly face the dilemma of how to
combine/prioritize multiple effective treatments.
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